Background

NDM-Mexico Feb 2015 - Nov 2016 Evolution
 

NDM has a growing spread of research relying on collaborations in Mexico and Latin America, and on direct access to infrastructure or patient cohorts in Mexico itself. In addition, there are a growing number of scientists and research institutes based in Mexico who are seeking collaborations abroad.

In response to these needs, NDM is hosting an initiative to support the creation of research infrastructure and research capacity in Mexico. In addition, we are continuing to build on our ‘direct’ collaborative research projects with Mexican scientists and students. Working together with all our partners, we aim to foster vaccine-development and genomics research capacity –topics that also have applications in immunology, inflammation, infections, chronic diseases and cancers.

To achieve these aims, NDM is working in partnership with several Mexican research institutions, including:

- Benemérita Universidad Autónoma de Puebla (BUAP);

- El Colegio de la Frontera Sur (ECOSUR);

- Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (ENCB-IPN);

- Instituto de Biotecnología, Universidad Nacional Autónoma de México (IBT-UNAM);

- Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI (IMSS);

- Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM Campus Cd de México);

- Laboratorio Estatal de Salud Pública de Michoacán (LESPM);

- Universidad Michoacana San Nicolás de Hidalgo (UMSNH); and

- Universidad Veracruzana (UV).

The initial proposal envisages the formation of a vaccine development programme for Zika, dengue and chikungunya - major diseases affecting Mexico. These diseases affect a large number of people from a substantial population at risk, and hampers Mexican social and economic development. A protective vaccine against these diseases will have a major impact on the Mexican and Latin American health systems and economic productivity.

This initial research capacity development will also underpin the development of vaccines against tropical diseases such as malaria and dengue, and emerging and neglected diseases such as Chagas, chikungunya and Zika, which now pose a major threat as far north as the southern United States.